Katharina Leucht - Concepedia

Author

Katharina Leucht

University Hospital of Zurich ORCID

Also Known As

Christoph Beglinger, K Leucht, K. H. Leucht, K. Leucht, Katharina Leucht, Leucht, K., Leucht, Katharina

Publications

560

Citations

H-Index

Concepts

All Affiliations

University Hospital of Zurich University of Zurich National Center for Tumor Diseases University Hospital Carl Gustav Carus Jena University Hospital

About

Katharina Leucht is an author at University Hospital of Zurich specializing in immunology, medicine, and gastroenterology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	118
2	Immunology	4	4	118
3	Gastroenterology	2	2	74
4	Allergy	1	1	60
5	Pathology	1	1	14

Katharina Leucht

Publications

432

Citations

H-Index

Page 1

	Year	Citations
The Proton-activated Receptor GPR4 Modulates Intestinal Inflammation Yu Wang, Cheryl de Vallière, Pedro Henrique Imenez Silva, Journal of Crohn s and Colitis	2017	84
Sphingomyelin induces cathepsin D-mediated apoptosis in intestinal epithelial cells and increases inflammation in DSS colitis Anne Fischbeck, Katharina Leucht, Isabelle Frey‐Wagner, Gut	2010	81
Crohnʼs disease-associated polymorphism within the PTPN2 gene affects muramyl-dipeptide-induced cytokine secretion and autophagy Michael Scharl, Jessica Mwinyi, Anne Fischbeck, Inflammatory Bowel Diseases	2011	76
Burrowing is a sensitive behavioural assay for monitoring general wellbeing during dextran sulfate sodium colitis in laboratory mice Paulin Jirkof, Katharina Leucht, Nikola Cesarovic, Laboratory Animals InflammationAnimal PhysiologyLaboratory MiceDrinking WaterAllergy	2013	60
BCL-2 Modifying Factor (BMF) Is a Central Regulator of Anoikis in Human Intestinal Epithelial Cells Martin Hausmann, Katharina Leucht, Christian Ploner, Journal of Biological Chemistry	2011	52
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial Marc‐Oliver Grimm, Emilio Esteban, Philippe Barthélémy, The Lancet Oncology UrologyImmunotherapeutic BoostGenitourinary CancerMedicineImmunology	2023	29
Sphingomyelin and phosphatidylcholine contrarily affect the induction of apoptosis in intestinal epithelial cells Katharina Leucht, Anne Fischbeck, Michaela Caj, Molecular Nutrition & Food Research	2013	21
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial Marc‐Oliver Grimm, Christine Barbara Grün, Günter Niegisch, The Lancet Oncology Tumor ImmunologyMedicineImmunologyImmune Checkpoint InhibitorImmunotherapy Approach	2023	15
Lack of transketolase-like (TKTL) 1 aggravates murine experimental colitis Susanne Bentz, Theresa Pesch, Lutz Wolfram, American Journal of Physiology-Gastrointestinal and Liver Physiology Chronic Inflammatory DiseasesImmunologyGastroenterologyPathologyImmune Regulation	2011	14

Page 1